Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + irinotecan + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Yakult Honsha
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This drug is a combination chemotherapy regimen consisting of three cytotoxic agents—5-fluorouracil (5-FU), irinotecan, and oxaliplatin. It is used primarily in the treatment of advanced or metastatic colorectal cancer and pancreatic cancer. Each component has a distinct mechanism of action: - 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and replication. - Oxaliplatin is a platinum-based agent that forms DNA crosslinks, leading to apoptosis. The combination exploits synergistic effects to improve response rates compared to single-agent therapy or two-drug regimens. This regimen can cause significant toxicities including neutropenia, neuropathy (from oxaliplatin), diarrhea (from irinotecan), mucositis, and risk of infusion reactions[1][2][3].
- Other names
- FOLFIRINOX without leucovorin5-FU + irinotecan + oxaliplatin
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + irinotecan + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + irinotecan + oxaliplatin.